Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant.

It was claimed to be superior to meprobamate, which would eventually replace emylcamate.

The therapeutic index in mice was also established: Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35.

The first patented synthesis involved treating that alcohol with potassium cyanate and trichloroacetic acid.

[3] In 1963, an improved synthesis was reported using sodium cyanate and trifluoroacetic acid.